As of the latest Form 4 filed Jun 18, 2026.
What Madrigal Pharmaceuticals Inc insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 29 most recent filings for MDGL.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-06-18 | 2026-06-17 | Taub Rebecca Director | AAward | +454.00 | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-18 | 2026-06-17 | Levy Richard S Director | AAward | +454.00 | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-18 | 2026-06-17 | FOUSE JACQUALYN A Director | AAward | +454.00 | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-18 | 2026-06-17 | Daly James M Director | AAward | +454.00 | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-18 | 2026-06-17 | Brennan Daniel J. Director | AAward | +404.00 | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-18 | 2026-06-17 | BAKER BROS. ADVISORS LP Director | AAward | +908.00 | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-18 | 2026-06-17 | BAKER BROS. ADVISORS LP, Director | AAward | +908.00 | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-01 | 2026-06-01 | Soergel David Chief Medical Officer | SSale | −1.04K | $495.74 | $517K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-06 | Dier Mardi EVP and CFO | SSale | −40.00 | $437.65 | $17.5K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-06 | Dier Mardi, EVP and CFO | SSale | −80.00 | $436.69 | $34.9K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-06 | Dier Mardi, EVP and CFO | SSale | −80.00 | $435.32 | $34.8K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-06 | Dier Mardi, EVP and CFO | SSale | −160.00 | $434.20 | $69.5K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-06 | Dier Mardi, EVP and CFO | SSale | −116.00 | $432.56 | $50.2K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-06 | Dier Mardi, EVP and CFO | SSale | −120.00 | $430.90 | $51.7K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-06 | Dier Mardi, EVP and CFO | SSale | −40.00 | $429.58 | $17.2K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-06 | Dier Mardi, EVP and CFO | SSale | −160.00 | $429.00 | $68.6K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-06 | Dier Mardi, EVP and CFO | SSale | −80.00 | $427.85 | $34.2K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-06 | Dier Mardi, EVP and CFO | SSale | −420.00 | $426.86 | $179K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-06 | Dier Mardi, EVP and CFO | SSale | −40.00 | $425.08 | $17.0K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-06 | Dier Mardi, EVP and CFO | SSale | −646.00 | $431.94 | $279K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-06 | Sibold William John President and CEO | SSale | −1.66K | $431.94 | $718K | No | Form 4 ↗ |
| 2026-03-06 | 2026-03-06 | Kelley Shannon T General Counsel | SSale | −360.00 | $431.94 | $155K | No | Form 4 ↗ |
| 2026-03-06 | 2026-03-06 | Huntsman Carole Chief Commercial Officer | SSale | −419.00 | $431.94 | $181K | No | Form 4 ↗ |
| 2026-03-06 | 2026-03-06 | Taub Rebecca Director | SSale | −491.00 | $431.94 | $212K | No | Form 4 ↗ |
| 2026-03-06 | 2026-03-04 | Dier Mardi EVP and CFO | AAward | +5.21K | $0.00 | $0.00 | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-04 | Sibold William John President and CEO | AAward | +15.0K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-06 | 2026-03-04 | Kelley Shannon T General Counsel | AAward | +4.02K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-06 | 2026-03-04 | Huntsman Carole Chief Commercial Officer | AAward | +3.99K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-06 | 2026-03-04 | Soergel David Chief Medical Officer | AAward | +4.37K | $0.00 | $0.00 | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also MDGL’s full analysis or the market-wide insider trading feed. The tabs above jump to MDGL’s other SEC data.
Source: SEC Form 4 filings for MDGL, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.